Flagship · Bulletin

Macro rationale

Nothing in this wake moves the regime. Credit and vol are unambiguously risk-on (HY OAS 2.65 vs 2.73 sma; VIX 14.32, -21% vs 200d), the curve is positively sloped (2s10s +0.47), and breadth is adequate at 63% of sectors above their 50d. Against that, the QQQ extension escalator is firing at +9.31% vs 200d with no momentum confirmation (wRSI 58.5/64.2, neither ≥70), and the macro backdrop the desk has run since August — contracting payrolls into above-target CPI with a Warsh Fed pinned or leaning hawkish — is unchanged. That combination is the definition of NEUTRAL: loose financial conditions sitting on top of a late-cycle labor crack. Rotation confirms the pillar tilts rather than changing them: XLE +9.93pp vs SPY on WTI +11.62% 1m (energy +3), ITA -9.96pp (defense -3), XBI +5.81pp and XLV +4.04pp. Compute is dead flat at +0.84pp — this week's compute moves (MU +5.9%, ASML +3.9%, TSM +2.6%, AVGO flat after a 0.7% guide shortfall) are dispersion inside an intact capex line, not a directional flow. Cash stays at 19.41%, inside the extension-escalated 25% ceiling and well above the 14% working reserve. I am moving it only because I am funding a named open (AEIS), which is the doctrine's permitted cause — not because my regime read changed.

Thesis

One ticket. Every other name is a verbatim hold at entry weight, delta 0. The trigger names break nothing. MU +5.9% on the HBM ramp is the opposite of its unwind condition (SCA book erosion / HBM oversupply). ASML +3.9% on the same read, with a 62 score reflecting China export-control overhang, not a book-to-bill break. AVGO's Q4 guide missed by 0.7% while AI silicon grew 221% to a ~$16.7B run-rate — its stated unwind is stalling BELOW $25B, not growing toward it; at RSI 37 and -3.2% vs 200d I am not trimming a washed-out franchise on a rounding error. NEM's Zacks downgrade sits against a $1.95B Barrick settlement that removed an overhang. KTOS beat EPS by 61.5% and raised guidance while the stock fell — that is a price fact, not a thesis fact, and my unwind names backlog cancellations, of which there are none. HEI at 54x forward presses my invalidation, but that clause requires decelerating growth and Q2 was record net income +49% on sales +25%. FSLR I pass: the red team is right that 45X credits are the earnings, and OBBBA is phasing them down with FEOC traps — the named tailwind is turning, which is a disqualifier, not a discount. The one action: open AEIS as a 2.5% starter. It is the plumbing under the same HBM/WFE capex line MU is riding, plus a named 800VDC rack ecosystem position, and it enters at RSI 45 / -6% vs 200d rather than +67% extended. Starter size, not full, because the 38% gross margin and the MKS/Comet/Delta competitive set are real. Scale-in and kill cr

Reflection

Compute dispersion, not direction: MU +5.9%, ASML +3.9%, AVGO flat on a 0.7% guide miss — one capex line read three ways. Zero funder reversals book-wide again.

Ninth consecutive wake where the trigger was a price move and the answer was 'thesis intact'. I should treat that as information about the sentinel, not about the book — the ≥5% single-day rubric fires on volatility, and volatility in a capex boom is dispersion. What I did change: I stopped parking cash waiting for a foundation sleeve that is mechanically un-openable, and instead bought the plumbing under the flow I already own. AEIS is deliberately a starter, not a conviction slot — the 38% gross margin genuinely is a weaker moat than anything else in compute, and the red team's Delta/Vertiv

Positions (17)

• MUMicron Technologycompute

  hold3.86%87
  flow acceleratingconf

  Funder

  Only US-domiciled leading-edge DRAM/HBM franchise: 84.6% gross margin, FCF positive, and after two decades of cycle abuse a three-player HBM oligopoly that is finally capacity-disciplined and pre-sold. Named flow: the 14-16 Strategic Customer Agreements (~$100B contracted, customer deposits taken) plus NVIDIA's disclosed ~$1.3T 2027 hyperscaler capex outlook funding HBM4 allocation.

  Unwind

  Erosion of the SCA contract book or customer deposits being returned; HBM oversupply as 2027 capacity lands; CXMT converting its ~11% DRAM share and $8.6B Shanghai IPO into leading-edge HBM share; a named hyperscaler capex cut; or gross margin rolling back toward mid-cycle on ASP declines.

  Catalyst

  FQ4 earnings and FY27 HBM allocation commentary; CXMT Shanghai IPO pricing and any disclosed HBM roadmap.

  Scenarios · 12mo targets

  $1,150.00 base

  $1,450.00 bull — HBM4 allocation sells out through 2028 at rising ASPs while DRAM bit supply stays disciplined; SCA book extends and memory earns a structural-scarcity multiple.

  $650.00 bear — 2027 capacity from all three players lands together, CXMT takes commodity DRAM share on price, ASPs roll and the cycle reprices a peak-earnings multiple.

• TSMTaiwan Semiconductor Manufacturingcompute

  hold5.83%86
  flow acceleratingconf

  Funder

  Effective foundry monopoly at <=3nm — every meaningful AI accelerator routes through it. >50% gross margin, prodigious FCF, famously disciplined capex, ~73% foundry and ~90% advanced-node share. Named flow: NVIDIA's disclosed ~$1.3T 2027 hyperscaler capex line plus the CHIPS $6.6B Arizona award, both of which convert directly into leading-edge wafer bookings.

  Unwind

  Gross margin sustained <50% for two consecutive quarters; a rival closing the leading-edge yield gap; a Taiwan-strait event Arizona capacity cannot offset; or CoWoS advanced-packaging bookings decelerating as hyperscaler orders normalise.

  Catalyst

  Monthly revenue prints and the October quarterly report with 2027 capex guidance; CoWoS capacity expansion disclosures.

  Scenarios · 12mo targets

  $520.00 base

  $620.00 bull — N2 ramps on schedule with CoWoS still oversubscribed; pricing power on advanced nodes holds and TSMC captures a rising share of AI silicon value.

  $340.00 bear — A Taiwan-strait escalation or an abrupt hyperscaler digestion quarter cuts leading-edge utilisation while Arizona ramp costs weigh on margin.

• NVDANVIDIAcompute

  hold3.61%74
  flow steadyconf

  Funder

  AI-accelerator franchise with the CUDA software moat — 75% gross margin, fortress balance sheet, and developer lock-in no ASIC rival has replicated in a decade. Named flow: Q2 revenue $96.2B (+106% YoY) with ~$279B of disclosed supply commitments, and the company's own ~$1.3T 2027 hyperscaler capex disclosure naming the customers funding it.

  Unwind

  Data-center revenue YoY <20% for two consecutive quarters; gross margin breaking below the guided 71-72% floor because memory cost cannot be passed through; hyperscaler in-sourcing displacing Blackwell/Rubin across multiple named accounts; or export-control tightening removing China revenue outright.

  Catalyst

  Next quarterly print with Rubin ramp commentary; any US compute export-control amendment.

  Scenarios · 12mo targets

  $275.00 base

  $350.00 bull — Rubin ramps into an undersupplied market, networking attach keeps compounding, and inference demand broadens the customer base beyond the top five buyers.

  $165.00 bear — Memory cost inflation compresses gross margin below the 71% floor while hyperscaler ASIC in-sourcing and power constraints slow the buildout.

• ASMLASML Holdingcompute

  hold2.96%62
  flow steadyconf

  Funder

  EUV / High-NA monopoly — the single most irreplaceable tool in advanced semis, with no commercial-scale alternative at 2nm, a multi-year backlog, ~50% gross margin and an installed-base service annuity that carries it through order troughs. Named flow: TSMC/Samsung/Intel 2026-28 EUV orderbook, and Norway's GPFG plus large AM holders still on the register.

  Unwind

  Book-to-bill <0.7 for three consecutive quarters; a Dutch/US export-control tightening removing a material share of the orderbook; or a credible non-EUV patterning alternative reaching production at a leading-edge customer.

  Catalyst

  October 14 earnings — bookings print is the decisive read on the 2027 EUV/High-NA order cycle.

  Scenarios · 12mo targets

  $1,950.00 base

  $2,400.00 bull — 2027 EUV bookings inflect on N2/A16 and memory capacity adds; High-NA converts from evaluation tools to volume orders at two or more customers.

  $1,250.00 bear — China restrictions widen further and logic customers stretch tool deliveries; bookings stay soft for three quarters and the backlog visibility premium deflates.

• AVGOBroadcomcompute

  hold2.92%63
  flow steadyconf

  Funder

  Custom-silicon ASIC leader (~70% share) plus the VMware infrastructure-software lock-in — 69.5% gross margin, huge FCF, $7B+ annual buyback, a serial dividend grower, and Hock Tan's capital-allocation record. Named flow: Google TPU multi-generation, Meta MTIA and the Anthropic ~3.5GW ASIC programs, with Q3 AI semiconductor revenue +221% YoY to a ~$16.7B run-rate.

  Unwind

  AI custom-chip revenue stalling below a ~$25B annual run-rate; full hyperscaler in-sourcing displacing the ASIC design franchise across multiple named accounts; VMware renewal churn breaking the software annuity; or a leveraged, value-destroying acquisition breaking the capital-allocation record.

  Catalyst

  Q4 print — whether the $34.8B guide proves conservative and whether a fourth named XPU customer is disclosed.

  Scenarios · 12mo targets

  $420.00 base

  $520.00 bull — A fourth and fifth XPU customer ramp, AI revenue clears the $25B run-rate, and VMware renewals confirm the software annuity at high margin.

  $260.00 bear — Google or Meta pulls XPU design in-house, AI growth decelerates off the 221% base, and VMware price increases drive measurable enterprise churn.

• ANETArista Networkscompute

  hold2.60%65
  flow steadyconf

  Funder

  Durable hyperscaler-networking franchise and a consistent share-gainer since 2004 — 62.9% gross margin, ~45% GAAP operating margin, zero debt, and the single-image EOS software moat that makes rip-and-replace expensive. Named flow: Microsoft and Meta as disclosed >10% customers funding record $3B quarterly revenue, plus AI back-end Ethernet displacing InfiniBand in named cluster builds.

  Unwind

  Microsoft+Meta combined concentration >50% with revenue decelerating; Spectrum-X or whitebox displacing EOS in a NAMED hyperscaler footprint; or gross margin breaking below ~60% as AI-cluster mix dilutes campus pricing.

  Catalyst

  Next quarterly print with 2027 AI-networking revenue target and customer-concentration disclosure.

  Scenarios · 12mo targets

  $225.00 base

  $280.00 bull — Ethernet keeps taking AI back-end share from InfiniBand, the 2027 AI networking target is raised, and campus/enterprise diversifies the customer base.

  $140.00 bear — NVIDIA Spectrum-X wins a named hyperscaler back-end and whitebox pricing compresses gross margin below 60% while the top-two concentration rises.

• GEVGE Vernovaenergy

  hold5.71%61
  flow acceleratingconf

  Funder

  Gas-turbine and grid franchise with genuine pricing power — heavy-duty turbines effectively sold out through 2030, 10-20% price realization on new orders, and an installed-base service annuity that compounds off equipment sold decades ago. Named flow: a record $176B backlog, a $400M DOE SMR grant, Norway's GPFG added post-spin, and hyperscaler power-capex pull-through as the DOE ~100GW-by-2030 gri

  Unwind

  Gas-turbine backlog cancellation or a named hyperscaler power-capex cut; wind-segment losses widening enough to consume gas-segment profit; or the order book ceasing to grow as price realization on new slots fades.

  Catalyst

  Next quarterly backlog and orders disclosure; BWRX-300 Clinch River/Darlington construction milestones.

  Scenarios · 12mo targets

  $1,120.00 base

  $1,350.00 bull — Backlog compounds past $200B with 10-20% price on new slots, electrification services margin expands, and SMR converts from grant to firm order book.

  $700.00 bear — A hyperscaler power-capex pause cancels turbine slots and wind-segment charges keep consuming gas profit, collapsing the consolidated margin story.

• SCCOSouthern Copperenergy

  hold9.63%67
  flow steadyconf

  Funder

  Tail-risk hedge slot (§5.3): lowest-cost major copper producer with the industry's largest reserve base, 67.6% gross margin, FCF positive with a large dividend, and Grupo Mexico control enforcing capital discipline through the cycle. Named flow: the $20.5B investment plan with $10.3B earmarked for Tia Maria, Los Chancas and Michiquillay, 2026 production guidance raised to 917kt, and a structural c

  Unwind

  Copper price collapse breaking the deficit thesis; Tia Maria / Los Chancas permitting reversal; a dividend cut signalling balance-sheet stress; or a Peruvian/Mexican fiscal or royalty change materially taxing away the cost advantage.

  Catalyst

  Tia Maria construction milestones and Los Chancas permitting decisions; quarterly production and cash-cost prints.

  Scenarios · 12mo targets

  $225.00 base

  $275.00 bull — The copper deficit widens as grid and datacenter demand compounds while Tia Maria permits clear, adding low-cost tonnes into a tight market.

  $150.00 bear — A China-led industrial slowdown breaks the deficit, copper reverts toward marginal cost and Peruvian permitting stalls the growth pipeline again.

• NEMNewmont Corporationenergy

  hold6.35%83
  flow steadyconf

  Funder

  Tail-risk equity hedge (§5.3): largest gold producer with tier-1 long-life assets, strong post-Newcrest FCF and dividend, and visibly improving cost discipline after the divestiture program. Named flow: sustained central-bank gold accumulation plus the $1.95B Barrick Nevada JV settlement that removes a long-standing operational overhang and frees FCF optionality under a frozen-Fed stagflation regi

  Unwind

  Cost overruns or mine disappointments breaking FCF and the dividend; durable disinflation plus a real-rate surge removing the stagflation-hedge rationale; or the Nevada JV settlement failing to convert into the promised production and cost improvement.

  Catalyst

  Next quarterly production and AISC print — whether the 13% YoY Q2 production decline reverses; September FOMC real-rate path.

  Scenarios · 12mo targets

  $150.00 base

  $185.00 bull — Real yields fall as the labor crack forces the Fed's hand, central banks keep buying, and Nevada JV synergies lift FCF and the dividend together.

  $95.00 bear — Durable disinflation lets real yields rise, gold de-rates, and the 13% production decline persists into cost overruns that pressure the dividend.

• KTOSKratos Defensedefense

  hold11.41%64
  flow softeningconf

  Funder

  Scarce non-prime supplier of attritable airframes (XQ-58A Valkyrie), hypersonics and turbine engines, with a decade of embedded program positions the primes cannot easily displace and vertical propulsion integration few competitors own. Named flow: the DoD MACH-TB 2.0 $1.45B IDIQ ceiling, Project Helios $68.3M, USMC Valkyrie modifications, and Q2 revenue +30.5% with FY guidance raised.

  Unwind

  Backlog or contract cancellations; margin failing to inflect through the drone ramp with FCF staying negative through FY2027; a DoD unmanned-systems funding cut in the FY27 appropriation; or a dilutive equity raise to fund the production scale-up.

  Catalyst

  FY27 defense appropriation / CR resolution (Dec 4 deadline) and the next MACH-TB and CCA task-order awards.

  Scenarios · 12mo targets

  $62.00 base

  $85.00 bull — CCA and MACH-TB task orders convert the IDIQ ceilings into revenue, the drone ramp inflects margin, and FCF turns positive ahead of FY2027.

  $34.00 bear — A continuing resolution delays new-start obligations, the drone ramp keeps consuming cash into FY2027, and a dilutive raise resets the equity story.

• HEIHEICOdefense

  hold10.23%68
  flow steadyconf

  Funder

  Defense/aero aftermarket compounder and a textbook 20-30 year franchise — the Mendelson family has owned and run it since 1957, compounding FCF above 20% through disciplined tuck-in acquisitions funded from cash flow, on PMA parts with FAA-approval barriers competitors cannot shortcut. Named flow: record Q2 net income +49% YoY on sales $1.375B (+25%), FSG and ETG both beating, plus NDAA mandatory

  Unwind

  Organic growth decelerating below 6% WITH margin compression; a value-destroying large acquisition breaking the tuck-in discipline; a Mendelson management succession break; or forward P/E above 50x AT decelerating growth (the multiple alone, on accelerating growth, is not the trigger).

  Catalyst

  Next quarterly print — FSG/ETG organic growth rate is the read on whether the 54x forward multiple is being earned.

  Scenarios · 12mo targets

  $370.00 base

  $440.00 bull — Commercial MRO and defense aftermarket both compound double-digit organically while tuck-in M&A keeps adding accretive margin, sustaining the premium multiple.

  $250.00 bear — Organic growth decelerates below 6% while the 54x forward multiple compresses toward the sector, a double hit with no valuation cushion.

• LLYEli Lillybiology

  hold5.22%74
  flow steadyconf

  Funder

  Premier pharma compounder — the tirzepatide franchise on 85.8% gross margin plus a manufacturing moat from the $27B capacity build rivals cannot replicate quickly, run by a team with a genuine record of reinvesting into the pipeline rather than buying growth. Named flow: oral orforglipron approved April 2026, retatrutide Phase 3 (~28% weight loss vs MariTide's 20%), and the Centessa orexin milesto

  Unwind

  Tirzepatide US script share falling >5pts to Novo over two quarters; retatrutide Phase 3 disappointing on safety or durability; IRA/MFP negotiation reaching the GLP-1 class with a material price cut; or Amgen/Novo oral entrants undercutting on price at scale.

  Catalyst

  Retatrutide Phase 3 readouts and orforglipron launch script trajectory; CMS negotiation list updates for the GLP-1 class.

  Scenarios · 12mo targets

  $1,350.00 base

  $1,600.00 bull — Retatrutide confirms best-in-class efficacy and orforglipron opens the oral market at scale; capacity built at $27B converts to volume rivals cannot serve.

  $880.00 bear — MFP negotiation reaches the GLP-1 class, Novo/Amgen orals compete on price, and script share erodes while the capacity build sits underutilised.

• VRTXVertex Pharmaceuticalsbiology

  hold4.34%82
  flow steadyconf

  Funder

  Durable biology compounder: the cystic-fibrosis monopoly (Trikafta/Alyftrek) is a self-funding cash engine on 85.3% gross margin with patent protection into the late 2030s and a fortress net-cash balance sheet, so it never depends on capital markets. Named flow: Q2 revenue beat $3.33B vs $3.23B with FY guidance raised to $13.10-13.20B, Casgevy sales +151% YoY, and suzetrigine opening a non-opioid

  Unwind

  The CF franchise eroding faster than non-CF revenue can replace it; the Crinetics integration destroying value; a suzetrigine commercial failure removing the diversification leg; or forward P/E pushing toward the 30x invalidation on decelerating growth.

  Catalyst

  Suzetrigine (Journavx) script uptake and payer coverage decisions; next quarterly Casgevy revenue print.

  Scenarios · 12mo targets

  $640.00 base

  $760.00 bull — Suzetrigine converts the non-opioid pain opportunity while Casgevy scales, giving VRTX a second and third revenue leg beyond CF ahead of schedule.

  $440.00 bear — Suzetrigine uptake disappoints on payer friction, Casgevy stays a niche, and the market reprices VRTX as a single-franchise CF company facing late-2030s expiry.

• ARGXargenxbiology

  hold4.26%69
  flow steadyconf

  Funder

  The Vyvgart/Vyvgart Hytrulo (efgartigimod) FcRn autoimmune franchise: first-mover platform with a decade of indication runway, commercial-stage, high-margin and net cash, so it does not depend on capital markets. Named flow: FDA expansion of gMG approval to all serotypes, the CIDP launch trajectory, Sanofi's riliprubart CIDP failure widening the competitive moat, and the completed Forte acquisitio

  Unwind

  Vyvgart revenue growth stalling; a pipeline indication failure in myositis or Sjogren's; a competitor FcRn entrant (J&J nipocalimab, UCB rozanolixizumab) taking measurable share; or the Forte deal turning into serial dilutive M&A that breaks the self-funded model.

  Catalyst

  Myositis and Sjogren's Phase 3 readouts; quarterly Vyvgart Hytrulo prefilled-syringe conversion rate.

  Scenarios · 12mo targets

  $1,230.00 base

  $1,500.00 bull — Myositis and Sjogren's read out positive, subcutaneous conversion accelerates, and FcRn becomes a multi-indication platform with no credible fast-follower.

  $780.00 bear — A pivotal indication misses, nipocalimab takes measurable gMG/CIDP share, and Vyvgart growth decelerates against a platform-priced multiple.

• NVSNovartis AGbiology

  hold2.77%51
  flow steadyconf

  Funder

  Top-5 global pharma with genuinely diversified in-market cash flow — Kisqali, Scemblix, Leqvio, Fabhalta, Cosentyx — on ~40% core operating margin and strong FCF, run by a management team whose capital allocation has been subtraction (Sandoz, Alcon spins) rather than empire-building. Named flow: positive Phase III remibrutinib data in relapsing MS showing superiority over Aubagio, and the Denton T

  Unwind

  Scale-in to ~5% requires two consecutive quarters of >=6% cc growth with core margin >=40%. Kill criteria: core margin below 35%, group revenue turning negative on the Entresto/Tasigna LOE cliff without Kisqali/Scemblix offsetting, or a large dilutive acquisition breaking the disciplined-allocation record.

  Catalyst

  Denton TX radioligand facility commissioning (H2 2026); remibrutinib MS regulatory filing path.

  Scenarios · 12mo targets

  $185.00 base

  $215.00 bull — Remibrutinib adds a multi-billion MS franchise, Kisqali and Scemblix outgrow the Entresto cliff, and radioligand capacity converts Pluvicto into a scaled platform.

  $135.00 bear — The Entresto LOE cliff outruns new launches, pelacarsen-style pipeline setbacks recur, and core margin slips below 35% on launch spend.

• BEAMBeam Therapeutics Inc. Common Stockbiology

  hold1.38%43
  flow steadyconf

  Funder

  Origin platform for base editing (David Liu science, Broad-licensed): single-base correction without double-strand breaks — the most differentiated editing chemistry in the field — with ~$1.21B cash funding BEAM-302 in AATD into 2028, so it does not face a near-term financing cliff. Named flow: BEAM-302 Alpha-1 dosing completed with a late-breaking oral presentation slot secured, plus disclosed AR

  Unwind

  Kill immediately on any grade 3+ hepatotoxicity or off-target signal in BEAM-302/301 (the Verve-101 precedent), on a discounted equity raise before the AATD pivotal readout, or on cash runway falling below 18 months without a named partner.

  Catalyst

  BEAM-302 late-breaking oral presentation with expanded AATD dose-escalation safety and total-AAT correction data.

  Scenarios · 12mo targets

  $40.00 base

  $75.00 bull — BEAM-302 shows durable total-AAT correction with clean liver safety, validating in-vivo base editing and drawing a large-pharma partnership on platform terms.

  $12.00 bear — A hepatotoxicity or off-target signal in the AATD dose escalation forces a hold, and the platform premium collapses ahead of a dilutive raise.

• AEISAdvanced Energy Industriescompute

  open2.50%+2.50pp69
  flow steadyconf

  Funder

  Advanced Energy: 45-year incumbent in precision RF/DC plasma power delivery, designed into etch and deposition process recipes at the major WFE OEMs — requalifying a power supply means requalifying the recipe, which is the switching cost the 38% gross margin understates. Net cash, buyback, focused on semi + datacenter after divesting low-margin industrial. Named flow: the same HBM/DRAM capacity ra

  Unwind

  Gross margin sustained below 36% on price competition from MKS/Comet; semiconductor-segment revenue declining two consecutive quarters as the WFE recovery slips; or the 800VDC datacenter socket publicly awarded to Delta/Vertiv with no AEIS production design-win. SCALE-IN to ~5% requires two consecutive quarters of >15% YoY semi revenue growth at GM >=40% PLUS a disclosed 800VDC production win. Any

  Catalyst

  Q3 print — semiconductor-segment revenue growth and gross-margin trajectory; any disclosed 800VDC rack-power production design-win.

  Scenarios · 12mo targets

  $330.00 base

  $410.00 bull — WFE recovery broadens beyond memory while AEIS converts an 800VDC rack-power design-in to volume; gross margin clears 40% and operating leverage compounds off trough EPS.

  $200.00 bear — WFE recovery slips, hyperscalers dual-source rack power to Delta/Vertiv at lower price, margins stay ~38% and the multiple compresses to a cyclical component supplier's.

Warnings

• §5.4 dry-powder: cash_pct 19.41% above base band top 15% allowed by §3b unfilled-sleeve headroom (+17.5pp, eff top 32.5%)

Conviction-lock actions

No conviction-lock refusals or overrides this run.

Cost breakdown

Per-call cost computed from cost.js pricing constants (Opus 4.7, Sonnet 4.6, Haiku 4.5). Cache-read tokens billed at 10% of input. See Cost & ROI for the rolling 30-day ledger.